Driehaus Capital Management LLC Has $13.96 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Driehaus Capital Management LLC trimmed its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 3.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,561,791 shares of the biotechnology company’s stock after selling 55,837 shares during the period. Driehaus Capital Management LLC owned about 2.77% of Astria Therapeutics worth $13,962,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ATXS. Cubist Systematic Strategies LLC bought a new stake in shares of Astria Therapeutics in the fourth quarter valued at about $137,000. BNP Paribas Financial Markets bought a new stake in shares of Astria Therapeutics in the 4th quarter worth approximately $50,000. Northern Trust Corp grew its holdings in shares of Astria Therapeutics by 4.5% during the 4th quarter. Northern Trust Corp now owns 458,234 shares of the biotechnology company’s stock worth $4,097,000 after purchasing an additional 19,893 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Astria Therapeutics during the fourth quarter valued at approximately $65,000. Finally, Voya Investment Management LLC raised its stake in shares of Astria Therapeutics by 367.4% in the fourth quarter. Voya Investment Management LLC now owns 71,708 shares of the biotechnology company’s stock valued at $641,000 after purchasing an additional 56,366 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Trading Down 3.9 %

NASDAQ ATXS opened at $4.23 on Friday. The firm has a market cap of $238.72 million, a price-to-earnings ratio of -2.02 and a beta of 0.45. Astria Therapeutics, Inc. has a 1-year low of $3.56 and a 1-year high of $12.92. The company has a 50 day moving average of $5.22 and a 200-day moving average of $7.66.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.01. On average, analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on ATXS. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Cantor Fitzgerald raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 29th. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. Five investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $30.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.